Phase 3 N=1,240 Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
Non Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 11.3; 8.9 Weeks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=9,306 Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications
Diabetes Mellitus, Type 2
Primary: Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Valsartan Versus Non-valsartan — 33.1; 36.8 Percentage of patients
Phase 3 N=1,391 ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer
Non-small Cell Lung Cancer · Lung Cancer
Primary: Progression-Free Survival (PFS) in the Overall Population — 17.3; 14 Weeks
Phase 3 N=932 Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
Essential Hypertension
Primary: Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to Week 8 Endpoint — -10.3; -6.6 mmHg
Phase 3 N=784 Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)
Novel 2009 Influenza H1N1
Primary: Percentage of Subjects With Seroconversion and HI Titer ≥1:40 in Children 3 to 17 Years of Age — 26; 83; 95; 92 Percentages of Subjects
Phase 3 N=1,523 Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) — 46; 8 mL — p=0.0003
Phase 3 N=1,568 Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) — 33; -25 mL — p=<0.0001
Phase 3 N=300 Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure
Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) — -15.4; -14.1 mm Hg
Phase 3 N=743 Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128)
Chronic Obstructive Pulmonary Disease
Primary: Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) — 65; -16 mL — p=<0.0001
Phase 3 N=933 Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) — 39; -10 mL — p=<0.0001
Phase 3 N=80 An Open-Label Study Of Celecoxib In Patients With Posttraumatic Pain
Pain
Primary: Patient Impressions at Final Visit (the Number of Participants Who Have Rated "Excellent" and "Good") — 70 Participants
Phase 3 N=136 Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance
Restless Legs Syndrome · Restless Legs Syndrome (RLS)
Primary: Adjusted Mean Change From Baseline in Wake Time During Sleep (WTDS) at Week 4/10 Measured by Polysomnography (PSG) (Sleep Study) Using Last Observation Carried Forward…
Phase 3 N=470 Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts
Genital Warts
Primary: Proportion of Subjects With Complete Clearance of All Warts (Both Presented at Baseline and Newly Emerged Warts) at End of Study — 0.191; 0.272; 0.103 participants
Phase 3 N=50 A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Active Rheumatoid Arthritis
Primary: Double-blind Period: Mean Synovitis Scores at Baseline As Measured by the Rheumatoid Arthritis Clinical Trials 6 (OMERACT 6) Rheumatoid Arthritis Magnetic Resonance…
Phase 3 N=1,254 Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension
Hypertension
Primary: Overall Mean Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Over 8, 16 and 24 Weeks — -25.34; -17.94; -19.81 mmHg